UBC Chooses THREAD to Expand Its Global Industry-Leading Decentralized Clinical Research Offering

THREAD's platform and services complement UBC's market-leading virtual evidence generation product, allowing organizations to perform DCTs globally using existing resources such as eConsent, eCOA, sensors, tablets, telehealth, and engaging patients who engage in UBC programs.

FREMONT, CA: UBC, a late-stage research and patient-support services organization, and THREAD, a technology and service provider enabling DCTs, has declared UBC's selection of THREAD to use decentralized approaches across studies in the UBC portfolio. The fully connected offering enables even more efficient decentralized approaches, faster program start-up timelines, and a more streamlined offering from data collection to actionable insights in a single platform.

"THREAD's approach to decentralized studies, continued investment in new solutions that surround evidence generation, patient engagement and connections to other third-party data, aligns perfectly with our goals to bring additional decentralized options to our current and future clients in the UBC portfolio," stated Brett Huselton, CBO of UBC. "Together, THREAD and UBC, underpinned by a three-year working relationship, are bringing new innovations to our clients and industry, helping to facilitate adoption of decentralized trials in global research."

THREAD's platform and services complement UBC's market-leading virtual evidence generation product, allowing organizations to perform DCTs globally using existing resources such as eConsent, eCOA, sensors, tablets, telehealth, and engaging patients who engage in UBC programs. UBC's current offerings include digital recruiting and interaction initiatives, in-home care assistance, clinical evaluations, and drug administration, as well as powerful real-world data infrastructure, data enrichment strategies, and quick analytics tools to help clients make better decisions faster.

"We are delighted to grow our ongoing partnership with UBC and help expand their DCT leadership in the CRO industry," stated John Reites, CEO of THREAD. "This partnership offers participants, trial sites, and biopharma unparalleled insights and experiences that set a new standard in decentralized clinical trials management. The entrepreneurial approach and culture between the organizations is a strong fit and we will continue to advance the offering as we win together in the market."